TGF- 1 induces proteinase-activated receptor 2 (PAR2) expression in endometriotic stromal cells and stimulates PAR2 activation-induced secretion of IL-6

Saito A, Atsushi Saito, Ako Saito, Yutaka Osuga, Osuga Y, Osamu Yoshino, Yoshino O, M Takamura, Masashi Takamura, Takamura M, Tetsuya Hirata, Yasushi Hirota, Kaori Koga, Miyuki Harada, Takemura Y, Yuri Takemura, Tetsu Yano, T Yano, Yano T, Yuji Taketani, Y. Taketani, Taketani Y
Human Reproduction · 2011 · vol. 26(7) , pp. 1892–1898 · doi:10.1093/humrep/der125 · PMID:21546388 · W2156316143
article OA: bronze CC0 ⤵ 20 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-17 ⓘ

Transforming growth factor-β1 increases proteinase-activated receptor 2 expression in endometriotic stromal cells, which enhances interleukin-6 secretion upon receptor activation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Proteinase-activated receptor 2 (PAR2) is a G-protein-coupled receptor that is activated by several serine proteases. PAR2 activation in endometriotic stromal cells (ESCs) has been implicated in the development of endometriosis but the regulatory mechanism of PAR2 expression in ESC is unknown. Our objective was to study the mechanism by which PAR2 expression may be regulated in endometriotic lesions. METHODS: Primary cultures of ESCs were treated with transforming growth factor-β (TGF-β) 1, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and the expression of PAR2 was examined by real-time quantitative PCR. ESCs pretreated with or without TGF-β1 were treated with PAR2 agonist peptide (PAR2AP) and the secretion of the pro-endometriotic cytokine, IL-6, was measured using a specific enzyme-linked immunosorbent assay. Effects of TGF-β type 1 inhibitor, SB431542, and PAR2 small interfering RNA (siRNA) on the TGF-β1 stimulation of PAR2 gene expression and PAR2AP-induced IL-6 secretion were also evaluated. To study intracellular signaling, effects of inhibitors of mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase (PI3K) and of Smad4 siRNA on the TGF-β1-induced PAR2 gene expression were studied. RESULTS: Only TGF-β1, but neither TNF-α nor IL-1β, increased gene expression of PAR2. Activation of PAR2 with PAR2AP increased the secretion of IL-6 from ESCs. As expected, TGF-β1 pretreatment dose-dependently enhanced the PAR2AP-induced increase in IL-6 secretion from ESCs. Treatment of ESCs with the TGF-β type 1 inhibitor, SB431542, inhibited both TGF-β1-stimulation of PAR2 gene expression and PAR2AP-induced IL-6 secretion. Transfection of ESCs with PAR2 siRNA produced a similar inhibition of IL-6 secretion. The TGF-β1-induced increase in PAR2 gene expression was repressed by inhibition of p38 MAPK, p42/44 MAPK or PI3K, but not by knockdown of Smad4 expression. CONCLUSIONS: In view of significant roles of PAR2 and IL-6 in endometriosis, the TGF-β1-induced increase in PAR2 expression may be an elaborate mechanism that augments the progression of the disease.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Interleukin-6 Receptors, Proteinase-Activated Stromal Cells Transforming Growth Factor beta1 Endometriosis Endometriosis Enzyme-Linked Immunosorbent Assay Female Gene Expression Regulation Gene Expression Regulation Humans Interleukin-1beta Interleukin-1beta Interleukin-6 MAP Kinase Signaling System MAP Kinase Signaling System Phosphoinositide-3 Kinase Inhibitors Protein Kinase Inhibitors Protein Kinase Inhibitors

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (43)

Cited by (21)

Source provenance

europepmc
last seen: 2026-08-07T06:07:27.085738+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:42.478857+00:00
License: CC0 · commercial use OK